Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715559 · ClinicalTrials.gov registry record · NA
Cysteamine Therapy for Major Depressive Disorder
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00715559 is a NA study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 3 participants.
The verdict
NCT00715559, a NA study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
Interventions
- DRUG cysteamine bitartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00715559
The ClinicalTrials.gov registry entry for NCT00715559 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cysteamine bitartrate is the first listed.
NCT00715559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00715559 about?
NCT00715559 is a clinical study titled "Cysteamine Therapy for Major Depressive Disorder". The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.
What is the current status of trial NCT00715559?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2008-07. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00715559?
The interventions under investigation include: cysteamine bitartrate (DRUG).
Who is sponsoring clinical trial NCT00715559?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.